Iptacopan

Fabhalta

200 MG CapsuleCanadaMarketedAuthorised 28 Mar 2025

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Iptacopan

Fabhalta

200 MG CapsuleCanadaMarketedAuthorised 28 Mar 2025

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

FabhaltaUnited States · 200MG BASE · capsule · Novartis

Documents

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Iptacopan
Strength: 200 MG
Dosage form: Capsule
Route: Oral
Register: Canada (Health Canada)
Status: Marketed
Authorised: 28 Mar 2025
Registration: DIN 02554313
Marketing authorisation holder: Novartis Pharmaceuticals Canada INC
ATC code: L04AJ08
Group: Antineoplastic and immunomodulating agents
Supply: PRESCRIPTION